title: A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
abstract: OBJECTIVE
  To investigate the clinicopathological features, treatment outcomes, and prognostic factors in patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type.
  
  
  METHODS
  We retrospectively reviewed the medical records of 115 patients diagnosed with extranodal NK/T-cell lymphoma, nasal type who were admitted to our hospital between January 1991 and June 2006.
  
  
  RESULTS
  In total, 107 patients were available for follow-up. After the completion of treatment, 48 patients (44.9%) achieved a complete remission. By the end of the follow-up period, 60 patients (56.1%) had died from local recurrence or metastases. The mean survival duration was 70.0 months, the median survival duration was 42 months, and the 5-year survival rate was 39.4%. The mean survival durations of the three treatment groups of chemoradiotherapy, radiotherapy and palliative treatment were 91.6, 60.1 and 17.6 months, respectively. The median survival durations were 72.0, 42.0 and 10 months, respectively. Patients treated with > 50 Gy had better local control and survival than the < 50 Gy group. However, there was no significant difference between patients having fewer than four cycles of chemotherapy and patients having more than four cycles. Multifactor Cox regression model analysis showed that B symptoms, gender, International Prognostic Index (IPI) score, disease stage and therapy were all independent prognostic factors.
  
  
  CONCLUSIONS
  The prognosis of extranodal NK/T-cell lymphoma, nasal type is poor and significantly influenced by B symptoms, gender, IPI score, clinical staging and the method of treatment. Chemoradiotherapy should be the first choice for treatment.
authors.affiliation: Head and Neck Carcinoma Department, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: P
authors.initials: P
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Zhao
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: F
authors.initials: F
authors.lastname: Wang
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Yang
authors.forename: F
authors.initials: F
authors.lastname: Fang
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: W Y
authors.initials: WY
authors.lastname: Wang
authors.forename: C
authors.initials: C
authors.lastname: Yi
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate